Refine by
Monoclonal Secondary Antibody Equipment Supplied In Australia
7 equipment items found
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
PSA-mAb is the invention of Professor David Ulmert formerly of Memorial Sloan Kettering and now ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
Starpharma’s DEP® technology provides enhanced therapeutic benefits to Antibody Drug Conjugates (ADCs) including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. The use of ADCs is an innovative and cutting-edge area in cancer therapy that continues to grow, and Starpharma has a number of partner programs in the area. ...
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
DUNP19 is the invention of Professor Ulmert at UCLA. ...
by:AdAlta Limited based inBundoora, AUSTRALIA
An i-body is a human protein that belongs to the class of next generation antibodies. The i-body is built on the scaffold of a human protein and engineered with two loops that mimic the shape of shark antibodies. These loops are responsible for binding or interacting with a particular target (in circulation or on a cell) that is causing disease. i-bodies are identified and developed using our ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
Mesoblast’s proprietary mesenchymal lineage adult stem cells (MLCs) are found in multiple tissues where they play vital roles in maintaining tissue ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, CXCR4 and demonstrates anti-fibrotic effects in several models of fibrosis. This was initially called AD-114. Following further development, AdAlta ...